Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVN424 in Parkinson's Disease Patients With Motor Complications
NCT06553027Phase 3Active, not recruiting
- Sponsor
- Cerevance
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of solengepras in Parkinson's disease (PD), sponsored by Cerevance. Started Sep 2024; status: active, not recruiting.
02
Drugs
solengepras
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06553027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553027.